APA

Robak T., Jin J., Pylypenko H., Verhoef G., Siritanaratkul N., Drach J., Raderer M., Mayer J., Pereira J., Tumyan G., Okamoto R., Nakahara S., Hu P., Appiani C., Nemat S. & Cavalli F. (20190610). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. : The Lancet. Oncology.

Chicago

Robak Tadeusz, Jin Jie, Pylypenko Halyna, Verhoef Gregor, Siritanaratkul Noppadol, Drach Johannes, Raderer Markus, Mayer Jiri, Pereira Juliana, Tumyan Gayane, Okamoto Rumiko, Nakahara Susumu, Hu Peter, Appiani Carlos, Nemat Sepideh and Cavalli Franco. 20190610. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. : The Lancet. Oncology.

Harvard

Robak T., Jin J., Pylypenko H., Verhoef G., Siritanaratkul N., Drach J., Raderer M., Mayer J., Pereira J., Tumyan G., Okamoto R., Nakahara S., Hu P., Appiani C., Nemat S. and Cavalli F. (20190610). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. : The Lancet. Oncology.

MLA

Robak Tadeusz, Jin Jie, Pylypenko Halyna, Verhoef Gregor, Siritanaratkul Noppadol, Drach Johannes, Raderer Markus, Mayer Jiri, Pereira Juliana, Tumyan Gayane, Okamoto Rumiko, Nakahara Susumu, Hu Peter, Appiani Carlos, Nemat Sepideh and Cavalli Franco. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. : The Lancet. Oncology. 20190610.